Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report

被引：0

作者：

Torres, Viviana ^{[1
]}

Gonzalez-Ortega, Guillermo ^{[1
]}

Suarez, Antoni ^{[1
]}

Garrido, Alicia ^{[1
,2
,3
,4
,5
]}

Camara, Ana ^{[1
,2
]}

Compta, Yaroslau ^{[1
,2
,3
,4
,5
]}

Valldeoriola, Francesc ^{[1
,2
,3
,4
,5
]}

机构：

[1] Hosp Clin Barcelona, Inst Neurociencies, Neurol Serv, Parkinsons Dis & Movement Disorders Unit, Catalonia, Spain

[2] Univ Barcelona, Neurol Serv, Parkinsons Dis & Movement Disorders Unit, Hosp Clin 1, Barcelona, Spain

[3] Univ Barcelona, Inst Clin Neurociencies, Maria Maeztu Excellence Ctr, IDIBAPS,ERN RND,CIBERNED,ISCIII, CB06 05 0018, Barcelona, Catalonia, Spain

[4] Lab Parkinson Dis & Other Neurodegenerat Movement, Barcelona, Spain

[5] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Inst Neurociencies,Dept Neurol, Barcelona, Catalonia, Spain

来源：

CLINICAL PARKINSONISM & RELATED DISORDERS | 2022年 / 7卷

关键词：

D O I：

10.1016/j.prdoa.2022.100150

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.

引用

页数：2

共 50 条

[31] Weight variation in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion
Fernandez-Rodriguez, B.
Dupouy, J.
Harroch, E.
Fabre-Delcros, M. H.
Barthelemy, C.
Loubiere, P.
Barange, K.
Brefel-Courbon, C.
Rascol, O.
Ory-Magne, F.
MOVEMENT DISORDERS, 2018, 33 : S137 - S137
[32] Management of chronic polyneuropathy associated with levodopa-carbidopa intestinal gel infusion in Parkinson's disease: Review of the strategies and perspectives
Cransac, C.
Dupouy, J.
Loubiere, P.
Ackett, B.
Cintas, P.
Courbon, C. Brefel
Rascol, O.
Magne, F. Ory
MOVEMENT DISORDERS, 2018, 33 : S142 - S142
[33] Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease
Moes, Harmen R.
Buskens, Erik
van Laar, Teus
LANCET NEUROLOGY, 2024, 23 (09): : 856 - 857
[34] Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal levodopa-carbidopa infusion
Rivero-de-Aguilar, Alejandro
Sesar, Angel
Fernandez-Pajarin, Gustavo
Ares-Pensado, Begona
Castro, Alfonso
REVISTA DE NEUROLOGIA, 2019, 69 (07) : 304 - 306
[35] Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel Versus Oral Administration of Levodopa-Carbidopa Tablets in Japanese Subjects with Advanced Parkinson's Disease: Pharmacokinetics and Pilot Efficacy and Safety
Othman, Ahmed A.
Chatamra, Krai
Mohamed, Mohamed-Eslam F.
Dutta, Sandeep
Benesh, Janet
Yanagawa, Masayoshi
Nagai, Masahiro
CLINICAL PHARMACOKINETICS, 2015, 54 (09) : 975 - 984
[36] Efficacy of levodopa-carbidopa intestinal gel compared to oral levodopa-carbidopa in advanced Parkinson's disease: Sensitivity and responder analyses
Boyd, J. T.
Fernandez, H. H.
Slevin, J. T.
Espay, A. J.
Standaert, D. G.
Pritchett, Y.
Zhang, W.
Chatamra, K.
Widnell, K. L.
Benesh, J.
MOVEMENT DISORDERS, 2013, 28 : S143 - S143
[37] Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience
Bohlega, Saeed
Abou Al-Shaar, Hussam
Alkhairallah, Thamer
Al-Ajlan, Fahad
Hasan, Nael
Alkahtani, Khalid
EUROPEAN NEUROLOGY, 2015, 74 (5-6) : 227 - 236
[38] Stable levodopa plasma levels with jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients
Nyholm, D.
Odin, P.
Johansson, A.
Chatamra, K.
Locke, C.
Freeman, S.
Dutta, S.
Othman, A. A.
MOVEMENT DISORDERS, 2012, 27 : S131 - S131
[39] Levodopa/Carbidopa Intestinal Gel Infusion Therapy: Focus on Gait and Balance
Rispoli, Vittorio
Andreasi, Nico Golfre
Penna, Giovanna
Preda, Francesca
Contini, Eleonora
Sensi, Mariachiara
MOVEMENT DISORDERS CLINICAL PRACTICE, 2018, 5 (05): : 542 - 545
[40] Levodopa-carbidopa interactionFirst report of an interaction with concomitant tolcapone leading to vitiligo: case report
Reactions Weekly, 2000, 784 (1) : 10 - 10

← 1 2 3 4 5 →